文献速递免疫规划慢病防控与筛查

囊性纤维化儿童接种减毒活流感鼻喷疫苗后的不良事件:两个流感季节的结果

Adverse events following live-attenuated intranasal influenza vaccination of children with cystic fibrosis: Results from two influenza seasons.
PubMed 文献 · Vaccine · 2017-07-31

2012和2013年两个流感季节,198例2-19岁囊性纤维化患者共接种264剂减毒活流感鼻喷疫苗(LAIV),前瞻性随访55天。接种后0-6天报告不良事件的风险较高,但多为良性自限性,严重不良事件多与疫苗无因果关系,呼吸道疾病抗生素处方风险未增加,肺部急性加重频率未增加。

要点

  • LAIV接种后0-6天不良事件报告风险较高,但多数为短暂自限性,通常持续1-2天。
  • 严重不良事件多与LAIV无因果关系,风险期与对照期相比未达统计学显著。
  • 风险期呼吸道疾病抗生素处方风险低于对照期,肺部急性加重频率未增加。

核心结论

  • LAIV接种后不良事件在0-6天最常见,但总体良性且自限,肺部急性加重频率未增加。

研究设计与样本

  • 前瞻性随访研究,2012和2013年两个流感季节共198例2-19岁囊性纤维化患者接种264剂LAIV,接种后随访55天收集不良事件。
  • 采用贝叶斯变点分析识别LAIV后不良事件报告风险较高的风险期,并用多变量零膨胀泊松回归估计风险期与对照期各不良事件的调整发病率比(aIRR)及95%可信区间(CrI)。

主要发现

  • 随访0-6天与对照期7-55天相比,严重不良事件报告风险aIRR 1.45(95% CrI 0.29-5.17),未达统计学显著;多数严重不良事件与LAIV无因果关系。
  • 随访0-6天与对照期7-55天相比,征集性症状报告风险较高,但症状发作短暂,通常持续1-2天。
  • 风险期与对照期相比,呼吸道疾病抗生素处方风险aIRR 0.48(95% CrI 0.23-0.91),未增加。
  • 肺部急性加重频率未增加。

关键数值与推荐

  • 严重不良事件aIRR 1.45(95% CrI 0.29-5.17),风险期为接种后0-6天,对照期为7-55天。
  • 呼吸道疾病抗生素处方aIRR 0.48(95% CrI 0.23-0.91),风险期为接种后0-6天,对照期为7-55天。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Despite the approved use of live-attenuated intranasal influenza vaccine (LAIV) for seasonal immunization of patients with cystic fibrosis (CF), many questions remain unanswered regarding the timing, duration, and types of adverse events that occur following administration of this vaccine. METHODS: In 2012 and 2013, 264 LAIV doses were administered to 198 patients aged 2-19 with CF. Vaccinees were followed prospectively for 55 days after vaccination (day 0) and information on adverse events was collected. Bayesian change-point analysis was used to identify the risk period following LAIV during which participants had a higher risk of reporting adverse events. Multivariable zero-inflated Poisson regression models were then used to estimate the adjusted incidence rate ratio (aIRR) and 95% credible interval (CrI) of reporting each adverse event in the risk period versus the control period. RESULTS: There was a higher risk of reporting serious adverse events (SAEs) (aIRR 1.45, 95% CrI (0.29, 5.17)) and solicited symptoms during days 0-6 of follow-up compared to control period days 7-55. However, most SAEs were not causally related to LAIV and the solicited symptom episodes were brief, usually lasting 1-2 days. There was no increased risk of antibiotic prescriptions for respiratory conditions in the risk vs. control periods (aIRR 0.48, 95% CrI (0.23, 0.91)). CONCLUSIONS: Adverse events were most common 0-6 days after LAIV administration but were generally benign and self-limiting. Pulmonary exacerbations did not increase in frequency.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Boikos C, Joseph L, Scheifele D, et al. Adverse events following live-attenuated intranasal influenza vaccination of children with cystic fibrosis: Results from two influenza seasons. Vaccine. 2017. PMID: 28774563. doi:10.1016/j.vaccine.2017.07.068

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。